Register Now
Why register?
 The leading web portal for pharmacy resources, news, education and careers January 20, 2019
Pharmacy Choice - Pharmaceutical News - German Biotech Gets FDA Approval to Start an Ulcerative Colitis Phase II Study [Arab Times (Kuwait)] - January 20, 2019

Pharmacy News Article

 1/12/18 - German Biotech Gets FDA Approval to Start an Ulcerative Colitis Phase II Study [Arab Times (Kuwait)]

Immunic Therapeutics, which closed a 31M Series A last September, specializes in the development of drugs for the treatment of chronic inflammatory diseases. At the moment, the company has two ongoing development programs, working on drugs for diseases like ulcerative colitis, Crohns disease, and psoriasis. The FDA has approved Immunics Investigational New Drug (IND) application, giving the company its permission to administer IMU-838 to humans in a Phase II study to test its efficacy against ulcerative colitis.

Ulcerative colitis is a form of inflammatory bowel disease that causes long-lasting inflammation and ulcers in the gastrointestinal tract, which affects around 700,000 people in the US. In particular, the condition affects the innermost lining of the large intestine and rectum. Symptoms tend to develop over time and can become debilitating, even leading to life-threatening complications. There is no cure but treatment improves symptoms and can lead to long-term remission.

Immunics candidate, IMU-838, is an oral immune modulator, which targets active immune cells by inhibiting dihydroorotate dehydrogenase, an important enzyme in metabolism. This affects the function of or induces cell death in certain subsets T-cells, Th17 and Th1, and B-cells without leaving the patient at risk of infections. So far, the pharmacokinetics and safety of IMU-838 have been tested successfully, and the company plans to start Phase II trials for both ulcerative colitis and Crohns disease (CD).

With diseases affecting the gastrointestinal tract being the third biggest cause of death in the world, it is reassuring to see a number of biotechs working in the field. Only yesterday, Heptares and Imperial College London signed an R&D collaboration to boost G protein-coupled receptor (GPCR) drug discovery for diseases of the gut. Since the turn of the year, TopiVert has also announced the completion of a Phase I trial testing its ulcerative colitis drug with reduced side effects.

Elsewhere, companies like Enterome are hoping to use the microbiome to treat conditions like Crohns disease, with evidence supporting the importance of the bacteria in our body accumulating rapidly. There is even research indicating that good bacteria can control our genes, playing a role in the prevention of cancer.

Immunic takes a more conventional approach to the treatment of an inflammatory, gastrointestinal disease with its small molecule inhibitor. However, if it can demonstrate good clinical efficacy for the treatment of ulcerative colitis in the upcoming Phase II trial, it could have a big impact.

(c) 2018 2017 Arab Times Kuwait English Daily. All Rights Reserved. Provided by SyndiGate Media Inc. (

Pharmacy News Index
  Drug Delivery Systems
  FDA Final Approvals
  Front Page Healthcare News
  Generic Drugs
  Hospital Industry
  Internet Pharmacy
  IT in Healthcare
  Medicare & Medicaid
  Over-the-Counter Drugs
  Pharm Industry Trends and Policy
  Pharmaceutical Development
  Pharmaceutical Industry


Last Chance
Jan 20: An Integrative Approach to Managing Arthritis
Last Chance
Jan 21: Identifying, Targeting and Managing Chronic Renal Failure
Jan 22: Medication Use During Pregnancy & Lactation
Jan 23: ADHD in Children & Adults: Etiology, Pathology, Pharmacotherapy
Jan 24: COPD Update for Pharmacy Professionals
Click for entire Webinar Calendar

Special Announcement

Free Membership
Enjoy Drug Search, industry newsletters and more...

Nursing Jobs
Are you a nurse looking for a job?

Check out the Nursing Job Source.

Your number one choice for nursing jobs.

Websites »
Copyright © 2019 Pharmacy Choice - All rights reserved.
Terms and Conditions | Privacy Statement